Health-related quality of life in the gender, race, and clinical experience trial

Judith Feinberg, Michael Saag, Kathleen Squires, Judith Currier, Robert Ryan, Bruce Coate, Joseph Mrus, Judith Feinberg, Michael Saag, Kathleen Squires, Judith Currier, Robert Ryan, Bruce Coate, Joseph Mrus

Abstract

Background. We report health-related QoL (HRQoL) from GRACE (Gender, Race, And Clinical Experience) study by sex and race over 48 weeks. Methods. 429 treatment-experienced adults (HIV-1 RNA ≥ 1000 copies/mL) received darunavir/ritonavir 600/100 mg twice daily plus an appropriate background regimen. QoL was measured by the Functional Assessment of HIV Infection (FAHI) questionnaire. Results. 67% women and 77% men, including 67.4% black, 76.0% Hispanic, and 73.8% white patients, completed the trial. Baseline total FAHI scores were similar between sexes and races. Total FAHI of the entire population improved by Week 4 (P < .05); near-maximum changes obtained by Week 12 were maintained through Week 48. Women and black patients demonstrated larger improvements in total FAHI versus men, and Hispanic and white patients, respectively. Conclusion. HRQoL improved in all sex and racial/ethnic groups. Sex-based and race-based differences in improvements in FAHI subscales may provide insight into subtle differences of HIV-1 and treatment on HRQoL in different populations.

Figures

Figure 1
Figure 1
Study disposition by (a) sex and (b) race. a“Other” classification was selected by the investigator as reason for discontinuation. bOlder patient taking too many concomitant medications; ARV: antiretroviral.
Figure 2
Figure 2
Mean change from baseline in total FAHI score in (a) the overall population and completersa, (b) by sex, and (c) by raceb (observed). *Statistically significant change from baseline (P < .05). aExcludes patients who discontinued the trial. bFour patients self-identified as Asian or other and were not included in the analysis by race due to small sample size; FAHI: functional assessment of HIV infection.

References

    1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine. 1998;338(13):853–860.
    1. Cunningham WE, Crystal S, Bozzette S, Hays RD. The association of health-related quality of life with survival among persons with HIV infection in the United States. Journal of General Internal Medicine. 2005;20(1):21–27.
    1. de Boer-van der Kolk IM, Sprangers MAG, Prins JM, Smit C, de Wolf F, Nieuwkerk PT. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS therapy evaluation in the Netherlands (ATHENA) cohort. Clinical Infectious Diseases. 2010;50(2):255–263.
    1. Mathews WC, May S. EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health and Quality of Life Outcomes. 2007;5, article 5
    1. Currier J, Bridge DA, Hagins D, et al. Sex-based outcomes of Darunavir-Ritonavir therapy: a single-group trial. Annals of Internal Medicine. 2010;153(6):349–357.
    1. Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research. 1997;6(6):572–584.
    1. Viala-Danten M, Dubois D, Gilet H, Martin S, Peeters K, Cella D. Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials. Quality of Life Research. 2010;19(8):1215–1227.
    1. Smith K, Garcia F, Ryan R, Falcon R, Tennenberg A, Mrus J. GRACE (Gender, Race And Clinical Experience): outcomes by race at week 48. In: Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, Calif, USA. Poster H-918, 12–15 September 2009.
    1. Figuero LSB, Luque PB, Martin TP, Sagrado MG, Bouza JME. Assessment of factors influencing health-related quality of life in HIV-infected patients. HIV Medicine. 2011;12(1):22–30.
    1. McDonnell KA, Gielen AC, Wu AW, O’Campo P, Faden R. Measuring health related quality of life among women living with HIV. Quality of Life Research. 2000;9(8):931–940.
    1. Mrus JM, Williams PL, Tsevat J, Cohn SE, Wu AW. Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research. 2005;14(2):479–491.
    1. Pérez IR, Olry de Labry Lima A, del Castillo LS, Baño JR, Ruz MAL, del Arco Jimenez A. No differences in quality of life between men and women undergoing HIV antiretroviral treatment. Impact of demographic, clinical and psychosocial factors. AIDS Care. 2009;21(8):943–952.
    1. Bing EG, Hays RD, Jacobson LP, et al. Health-related quality of life among people with HIV disease: results from the multicenter AIDS cohort study. Quality of Life Research. 2000;9(1):55–63.
    1. Cella D, Gilet H, Viala-Danten M, Peeters K, Dubois D, Martin S. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clinical Trials. 2010;11(1):18–27.
    1. Falcon R, Bridge DA, Currier J, et al. Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the GRACE (Gender, Race And Clinical Experience) study. Journal of Womens Health. 2011;20(7):1043–1050.
    1. DeSalvo KB, Fan VS, McDonell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. Health Services Research. 2005;40(4):1234–1246.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere